Headquartered in Waltham, MA Fiscal year ends December NASDAQ: ARDX ardelyx.com
Ardelyx is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines for significant unmet medical needs. The company markets two FDA-approved products in the United States: IBSRELA (tenapanor) for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults, and XPHOZAH (tenapanor) for reducing serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy. Both products are based on tenapanor, an NHE3 inhibitor. Ardelyx's pipeline includes a Phase 3 clinical trial (ACCEL) evaluating IBSRELA for chronic idiopathic constipation (CIC), multiple pediatric clinical trials for IBSRELA, and RDX10531, a next-generation NHE3 inhibitor in IND-enabling studies with potential applications across multiple therapeutic areas. The company works with partners to develop and commercialize its products outside the United States. Updated
Tuesday's top analyst upgrades and downgrades included Ally Financial, Apple, Ardelyx, Block, DocuSign, D.R. Horton, Enovix, EOG Resources, Ford, Futu, Micron Technology, Novavax, PayPal, Pfizer and TG Therapeutics.
Friday’s additional top analyst upgrades and downgrades were on Amarin, Ardely, Ball, Coupang, Hanesbrands, United Airlines, Vimeo and more.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including Apple, Array Technologies, CareDx and Vertex Pharmaceuticals.
Ardelyx is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines for significant unmet medical needs.
The Wall Street consensus 12-month price target for ARDX is $12.90.
